Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) PT at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average recommendation of “Hold” from the eleven ratings firms that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $4.79.

Several equities research analysts recently commented on the company. HC Wainwright reissued a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, StockNews.com assumed coverage on Marinus Pharmaceuticals in a research note on Sunday. They set a “sell” rating for the company.

Marinus Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ MRNS opened at $0.55 on Thursday. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $10.50. The company has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The stock has a 50 day simple moving average of $0.52 and a 200-day simple moving average of $0.82.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Marinus Pharmaceuticals in the 4th quarter valued at approximately $54,000. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals during the 3rd quarter worth approximately $104,000. Deltec Asset Management LLC acquired a new stake in Marinus Pharmaceuticals during the 4th quarter worth approximately $107,000. Finally, XTX Topco Ltd lifted its stake in Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.